Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • SGNBCMA-001 - Hoffman, James

  • Investigator:
    James Hoffman
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen

    IRB: 20180619

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SEATTLE GENETICS

    Enrolling Sites:

    Sylvester

    Title:

    SGNBCMA-001: A Phase 1 Study of SEA-BCMA in Patients With Relapsed Or Refractory Multiple Myeloma

    Eligibility Criteria - NCT03582033 *This information has been extracted from " www.clinicaltrials.gov"

  • REGN5458 - Hoffman, James

  • Investigator:
    James Hoffman
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20190220

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: REGENERON PHARM INC

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

    Eligibility Criteria - NCT03761108 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210776 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen

    IRB: 20210776

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SANOFI AVENTIS

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

    Eligibility Criteria - NCT04270409 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210954 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    Coordinator:

    IRB: 20210954

    SDG: Myeloma
    Disease Site(s):

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT04017130 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201316 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen

    IRB: 20201316

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)

    Eligibility Criteria - NCT04268498 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201536 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:
    RCemailImg Olivia Falcon Valdes
    RCphone +1 (305) 2438373

    IRB: 20201536

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: NCI

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications

    Eligibility Criteria - NCT04814615 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210341 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen

    IRB: 20210341

    SDG: Myeloma
    Disease Site(s):

    Sponsor: PFIZER

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    MagnetisMM-4 A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA

    Eligibility Criteria - NCT05090566 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210675 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:
    RCemailImg Alanna Vossen

    IRB: 20210675

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Janssen

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone asMaintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who AreMinimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

    Eligibility Criteria - NCT03901963 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220203 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    Coordinator:

    IRB: 20220203

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: ABBVIE

    Enrolling Sites:

    Sylvester

    Title:

    First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma

  • GO40515 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180638

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40515: A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating The Safety, Tolerability, Pharmacokinetics, And Efficacy OfMosunetuzumab (BTCT4465) In Combination With CHOP or CHP-PolatuzumabVedotin In Patients With B-Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT03677141 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20160656

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • S17-00978 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20180143

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: NYULMC

    Enrolling Sites:

    Sylvester

    Title:

    S17-00978:A Phase Ib/IIa Study Evaluating the Safety and Tolerability ofVitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations

    Eligibility Criteria - NCT03433781 *This information has been extracted from " www.clinicaltrials.gov"